Literature DB >> 3263182

Colonic perforation. An unusual complication of therapy with high-dose interleukin-2.

D Schwartzentruber1, M T Lotze, S A Rosenberg.   

Abstract

The majority (85%) of patients receiving high dose Interleukin-2 (IL-2) experience gastrointestinal side effects, namely nausea, vomiting and diarrhea. In this article we describe four cancer patients that developed localized necrosis or perforation of the colon during IL-2 treatment. They represent 1.3% of patients (n = 315) or 0.9% of treatment courses (n = 452). All underwent surgical intervention and survived to leave the hospital. No common etiologic factor was apparent. Two patients were subsequently retreated with IL-2 without complication. Localized colonic necrosis or perforation is a rare complication associated with high dose IL-2 treatments. Aggressive surgical intervention is advocated and retreatment following recovery is safe.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263182     DOI: 10.1002/1097-0142(19881201)62:11<2350::aid-cncr2820621116>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Interleukin 2.

Authors:  T J Hamblin
Journal:  BMJ       Date:  1990-02-03

2.  Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.

Authors:  G R Birchfield; J H Ward; B G Redman; L Flaherty; W E Samlowski
Journal:  West J Med       Date:  1990-06

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 4.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

Review 5.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

6.  A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.

Authors:  T J Hamblin; S Sadullah; P Williamson; J Stevenson; R Oskam; P Palmer; C R Franks
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.